1. New Zealand Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
BLIS Technologies Limited

BLIS Technologies Limited

BLT.NZ
BLIS Technologies LimitedNZ flagNew Zealand Exchange
0.02
NZD
- -
- -
21.75MMarket Cap
BLIS Technologies Limited
BLT.NZ
(New Zealand Exchange)

Recent

price

0.02

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
0.01
0.01
0.01
- -
- -
- -
0.01
0.01
- -
0.01
0.01
0.01
0.01
0.01
0.01
0.01
Revenue per Share
- -
-0.01
-0.01
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.01
- -
- -
0.01
0.01
- -
- -
- -
- -
- -
- -
0.01
0.01
0.01
0.01
0.01
Book Value per Share
0.01
- -
- -
0.01
0.01
- -
- -
- -
- -
- -
- -
- -
0.01
0.01
0.01
0.01
Tangible Book Value per Share
139
139
154
530
856
1,102
1,102
1,107
1,108
1,108
1,108
1,108
1,230
1,274
1,274
1,279
Basic Weighted Avg Shares
1
1
1
1
1
3
6
7
5
8
10
10
9
10
10
12
Sales/Revenue/Turnover
-68.66
-111.67
-123.72
-213.2
-165.64
-80.86
-24.96
-9.84
-19.62
-5.12
6.91
-3.18
-44.97
-24.35
-12.3
-10.25
Operating Margin (%)
- -
- -
1
1
- -
1
1
1
1
1
- -
- -
1
1
1
1
Depreciation Expense
- -
-1
-2
-2
-2
-1
-1
- -
-1
- -
2
1
-3
-1
1
1
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
7.18
5.95
Effective Tax Rate (%)
-35.18
-102.52
-118.2
-161.46
-122.01
-54.42
-14.5
-0.37
-19.72
4.7
15.34
5.47
-30.77
-13.57
6.16
7.25
Profit Margin (%)
3
1
-3
1
4
3
2
2
2
2
4
3
10
9
10
10
Working Capital
4
4
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
- -
- -
- -
LT Debt
1
- -
- -
3
6
5
4
4
3
3
5
6
12
11
11
12
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
-11
14.76
-5.57
- -
- -
-10.26
-8.99
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
10.8
33.57
10.06
- -
- -
5.82
7
Return on Capital (%)
-28.74
-239.75
- -
- -
-31.88
-25.01
-18.57
-0.6
-30.1
12.01
38.08
10.57
-30.5
-11.8
5.83
7.09
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
14.92%
25.81%
7.26%
Free Cash Flow
112.7%
229.42%
-15.11%
Net Income, GAAP
347.49%
-162.6%
29.72%
Sales/Revenue/Turnover
21.51%
2.56%
10.27%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
10
2024
- -
- -
- -
- -
10
2025
- -
- -
- -
- -
12

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Pharmicell Co., Ltd. (005690.KS)
Unity Biotechnology, Inc. (UBX)
Chiome Bioscience Inc. (4583.T)
Poniard Pharmaceuticals, Inc. PFD CV$2.4375 (PARDP)
Beijing Luzhu Biotechnology Co., Ltd. (2480.HK)
Ligand Pharmaceuticals Incorporated (LGND)
Business
BLIS Technologies Limited (NZX: BLT) is a biotechnology company that develops, manufactures, and commercializes advanced probiotic strains for targeted health applications, including oral, throat, dental, immune, and skin health. The company offers proprietary strains such as BLIS K12 (Streptococcus salivarius K12) for supporting ear, nose, and throat (ENT) health, immunity, and bad breath reduction; BLIS M18 (Streptococcus salivarius M18) for promoting teeth and gum health and dental hygiene; and BLIS Q24 (Micrococcus luteus Q24) for balancing the skin microbiome to enhance skin clarity and radiance; these strains are provided as ingredients for private label and customized solutions, as well as finished products including lozenges, serums, and supplements in formats such as probiotic serum, teeth and gums lozenges, fresh breath lozenges, and immune lozenges. BLIS Technologies Limited, founded in 2000 and headquartered in Dunedin, New Zealand, operates globally with key markets in North America, Asia-Pacific (including China), Europe, Middle East, Africa, and New Zealand, serving B2B partners in ingredient supply, private label manufacturing, and finished goods alongside direct-to-consumer channels via e-commerce and retail. Recent developments include a strengthened strategic alliance with Probi AB in October 2025, extending the technology license and distribution agreement to grant Probi exclusive rights for BLIS K12 and BLIS M18 strains in the USA, Canada, select EMEA markets, and newly for pet nutrition applications; a new five-year agreement with BioStix Pty Ltd (BSP) in July 2025 following settlement of a patent issue; a new distribution partnership with Wilson Consumer Products Limited for the New Zealand pharmacy channel; and robust first-half 2026 financial results announced in November 2025, featuring 28% revenue growth to $7.7 million driven by 39% B2B expansion and private-label gains in China.